949 related articles for article (PubMed ID: 31433920)
1. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
3. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S; Simonova M; Spicka I; Pour L; Kriachok I; Gavriatopoulou M; Pylypenko H; Auner HW; Leleu X; Doronin V; Usenko G; Bahlis NJ; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Gironella M; Jurczyszyn A; Robak P; Galli M; Wallington-Beddoe C; Radinoff A; Salogub G; Stevens DA; Basu S; Liberati AM; Quach H; Goranova-Marinova VS; Bila J; Katodritou E; Oliynyk H; Korenkova S; Kumar J; Jagannath S; Moreau P; Levy M; White D; Gatt ME; Facon T; Mateos MV; Cavo M; Reece D; Anderson LD; Saint-Martin JR; Jeha J; Joshi AA; Chai Y; Li L; Peddagali V; Arazy M; Shah J; Shacham S; Kauffman MG; Dimopoulos MA; Richardson PG; Delimpasi S
Lancet; 2020 Nov; 396(10262):1563-1573. PubMed ID: 33189178
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
[TBL] [Abstract][Full Text] [Related]
5. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
[TBL] [Abstract][Full Text] [Related]
6. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
7. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Gasparetto C; Schiller GJ; Tuchman SA; Callander NS; Baljevic M; Lentzsch S; Rossi AC; Kotb R; White D; Bahlis NJ; Chen CI; Sutherland HJ; Madan S; LeBlanc R; Sebag M; Venner CP; Bensinger WI; Biran N; Ammu S; Ben-Shahar O; DeCastro A; Van Domelen D; Zhou T; Zhang C; Bentur OS; Shah J; Shacham S; Kauffman M; Lipe B
Br J Cancer; 2022 Mar; 126(5):718-725. PubMed ID: 34802051
[TBL] [Abstract][Full Text] [Related]
8. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
9. Selinexor for the treatment of multiple myeloma.
Podar K; Shah J; Chari A; Richardson PG; Jagannath S
Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
[No Abstract] [Full Text] [Related]
10. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
11. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract][Full Text] [Related]
12. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
[TBL] [Abstract][Full Text] [Related]
17. Selinexor: First Global Approval.
Syed YY
Drugs; 2019 Sep; 79(13):1485-1494. PubMed ID: 31429063
[TBL] [Abstract][Full Text] [Related]
18. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L; Polprasert C; Hájek R; Illés Á; Wróbel T; Sureda A; Beksac M; Gonçalves IZ; Bladé J; Rajkumar SV; Chari A; Lonial S; Spencer A; Maison-Blanche P; Moreau P; San-Miguel JF; Richardson PG
Lancet Oncol; 2021 Jan; 22(1):142-154. PubMed ID: 33301738
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
